1. Home
  2. PK vs ANIP Comparison

PK vs ANIP Comparison

Compare PK & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park Hotels & Resorts Inc.

PK

Park Hotels & Resorts Inc.

HOLD

Current Price

$10.59

Market Cap

2.0B

Sector

Real Estate

ML Signal

HOLD

ANIP

ANI Pharmaceuticals Inc.

HOLD

Current Price

$81.12

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PK
ANIP
Founded
1946
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PK
ANIP
Price
$10.59
$81.12
Analyst Decision
Hold
Strong Buy
Analyst Count
11
7
Target Price
$11.45
$99.29
AVG Volume (30 Days)
3.1M
468.6K
Earning Date
10-30-2025
11-07-2025
Dividend Yield
9.50%
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.67
Revenue
$2,541,000,000.00
$826,880,000.00
Revenue This Year
$0.11
$43.41
Revenue Next Year
$2.07
$9.66
P/E Ratio
N/A
$48.82
Revenue Growth
N/A
48.87
52 Week Low
$8.27
$52.50
52 Week High
$16.23
$99.50

Technical Indicators

Market Signals
Indicator
PK
ANIP
Relative Strength Index (RSI) 49.70 36.38
Support Level $10.44 $77.99
Resistance Level $10.78 $85.09
Average True Range (ATR) 0.30 2.61
MACD 0.04 0.19
Stochastic Oscillator 64.35 41.60

Price Performance

Historical Comparison
PK
ANIP

About PK Park Hotels & Resorts Inc.

Park Hotels & Resorts owns upper-upscale and luxury hotels, with 22,395 rooms across 36 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Share on Social Networks: